Equities
Graubündner Kantonalbank posts record H1 profit as revenue rises 11%
Swiss regional lender reports CHF 137.2 million net income for the first half of 2025, driven by broad-based growth in interest and fee income. CET1 ratio climbs to 20.2%.
Siegfried maintains 2026 outlook after 2H gains from U.S., Australia sites
Swiss pharma services group posts 2.2% H1 sales growth to 633M CHF; core EBITDA margin rises to 22.4%. Three newly acquired sites expected to add $100M in 2026 revenue.
Anthropic IPO plans, Nvidia earnings test AI trade as tech stocks slip
Anthropic is preparing to file for a public listing by month-end, targeting a valuation above SpaceX's $75 billion IPO. Nvidia's earnings next week will further shape AI sector sentiment.
Swiss economic calendar: Q2 earnings, macro data due Aug 21-28
Investors face a packed week of Swiss half-year results, Q2 earnings and key macro indicators including GDP, tourism and labor data.
Lifestyle Communities posts FY26 turnaround with AUD 186.8m debt cut
Net debt fell 40.6% to AUD 273.7m as operating cash flow swung to AUD 94.9m. Shares rose 1.7% after FY26 profit after tax reached AUD 46.9m.
Sika sells €1 billion hybrid bond in two tranches to European investors
Swiss specialty chemicals group places 30NC5.75 and 30NC8.75 bonds at 4.50% and 5.00% yields, respectively, with S&P assigning 50% equity credit.
MAAS Group posts 37% EBITDA rise, lifts buyback plan to 20% of shares
Underlying EBITDA surged 37% to AUD 300.3 million in H2 2026, while revenue climbed 27% to AUD 1.3 billion. The group expanded its buyback program to 20% of issued capital over 12 months.
CSL shares rise 3.3% after FY26 results, buyback announced
Australia’s CSL advanced for a second day as investors digested stronger-than-expected earnings and a A$1.1 billion buyback program. Brokerage firms upgraded price targets following the FY26 results.
Super Retail FY26 sales rise to $4.2bn as profit slips on transformation costs
Australia’s Super Retail Group posted record annual sales but normalized profit fell 7% as higher transformation costs weighed on margins. Shares surged 15.3% on the update.
Sonic Healthcare posts 13% revenue rise but shares drop on FY2026 outlook
Australia’s largest pathology provider reported A$10.9 billion in revenue for FY2026, up 13% year-over-year, but its stock fell 9.2% after missing earnings expectations and flagging margin pressures in key markets.
Emeco’s FY26 results show maintenance shift boosts returns, buyback approved
Emeco Holdings reported a 5% rise in FY26 net profit as maintenance services drove revenue growth, while the board greenlit a 10% share buyback. Net debt fell to $127.1 million.
Emeco targets 20% ROC with $127.6m FY26 free cash flow
Australia’s largest mining equipment renter posts 16.9% return on capital, approves 10% buyback after FY26 results. Maintenance revenue now 50% of gross.
Codan posts 69% profit surge on defence, gold detector demand
ASX-listed Codan reported FY26 net profit of $175.2m, up 69% YoY, as defence and metal detection revenues surged. Shares rose 11.8% to $48.61.
Brambles FY26 profit hit by U.S. repair constraints, recovery plan outlined
Underlying profit rose 4% to $1.49 billion despite $90 million hit from U.S. repair bottlenecks, with a $25 million repair expansion plan set for FY28. Dividend maintained at 46.15 cents per share.
Goodman Group posts 10.1% FY2026 profit rise, targets 9% FY2027 EPS growth
Australia’s industrial and data center specialist Goodman Group reported a 10.1% jump in FY2026 operating profit to AUD 2.675 billion and set a 9% EPS growth target for FY2027. The group’s data center pipeline surged to AUD 19.7 billion.
Wolfspeed shares plunge 9% after weak earnings miss, guidance cut
Silicon carbide chipmaker reports adjusted loss of $2.26 per share, missing estimates by over 400%, as revenue falls 28% short of forecasts.
Merck, Moderna cancer vaccine trial shows 59% reduction in recurrence risk
Merck and Moderna’s mRNA cancer vaccine cut melanoma recurrence risk by 59% in late-stage trial, signaling a potential shift in oncology treatment. Data released Wednesday underscores the promise of personalized mRNA therapies.
Gore Street sells two Irish energy storage assets to internal fund
Transaction valued at or above prior NAV as Gore Street begins disposal program under 2026 strategy. Two Irish projects totaling 195 MW/390 MWh transferred to GS EU Fund.
Swiss Market Index dips 0.1% as Logitech, Richemont, Swiss Re fall
Heavyweights Roche and Lonza advance while Givaudan leads gains; Centiel surges 6.4% on strong half-year results and U.S. contract. Walmart drags U.S. markets lower after weak quarterly sales.
abrdn European Logistics Income sets 2.34 euro cent dividend for 2026
First interim dividend of 2.34 euro cents (2.00 pence) declared for year ending 2026, as company advances wind-down process with final asset sale expected in Q4.
DAX falls below 26,000 points for fourth straight session
German blue-chip index drops 0.42% as Brent crude approaches $100/barrel amid Middle East tensions. Continental gains on JPMorgan upgrade; Sartorius surges 6% on UBS call.
Telix Pharmaceuticals posts 146% EBITDA surge in H1 2026 as revenue climbs 22%
Precision medicine sales rose 27% year-over-year to $388 million, while full-year revenue guidance maintained at $950M-$970M. EBITDA reached $52M, up from $21M in H1 2025.
Goodman Group FY26 profit rises 15.7% on data centre demand
Data centres now account for 78% of Goodman Group's AUD 19.7 billion development pipeline as the industrial REIT reports a 15.7% rise in operating profit to AUD 2.675 billion. Shares dip 1.2% despite strong growth.
Swiss stocks rise; Geberit surges 7.4% on strong half-year results
Swiss market leads Europe as SMI gains 0.5% to 14,387; Roche and Novartis advance on pharma optimism, while insurance stocks lag amid bond-market pressures.